Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2020	Jun. 30, 2020
Current assets:
Cash and cash equivalents	$ 118.3	$ 163.7
Marketable investment securities	42.1	54.1
Prepaid expenses	12.5	13.8
Inventory	26.6	29.1
Trade accounts receivable	85.1	68.1
Prepaid taxes	107.9	0.0
Other receivables	2.0	2.9
Total current assets	394.5	331.7
Property, plant and equipment, net	36.7	37.0
Operating lease right-of-use assets	62.7	66.0
Long-term marketable investment securities	30.2	37.0
Intangibles, net	590.9	605.3
Goodwill	328.3	327.6
Other assets	1.2	0.0
Total assets	1,444.5	1,404.6
Current liabilities:
Accounts payable	19.1	21.7
Accrued liabilities	65.4	75.9
Current maturities of operating lease liabilities	13.6	13.5
Short-term contingent consideration	3.3	3.1
Deferred revenue	32.3	32.8
Total current liabilities	133.7	147.0
Unrecognized tax benefits	37.4	23.5
Long-term deferred taxes	75.3	26.6
Long-term debt	224.6	224.4
Noncurrent operating lease liabilities	53.5	56.9
Other long-term liabilities	10.7	8.0
Total liabilities	535.2	486.4
Commitments and contingencies
Stockholders’ equity:
Common stock, 75.2 and 74.7 shares outstanding at September 30, 2020 and June 30, 2020 respectively	0.8	0.7
Additional paid-in capital	1,101.2	1,096.6
Accumulated other comprehensive loss	(3.6)	(5.2)
Accumulated deficit	(189.1)	(173.9)
Total Myriad Genetics, Inc. stockholders’ equity	909.3	918.2
Non-controlling interest	0.0	0.0
Total stockholders' equity	909.3	918.2
Total liabilities and stockholders’ equity	$ 1,444.5	$ 1,404.6